sincalide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4627 25126-32-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sincalide
  • cholecystokinin-8
  • SQ-19844
  • SQ 19844
An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.
  • Molecular weight: 1143.27
  • Formula: C49H62N10O16S3
  • CLOGP: -4.65
  • LIPINSKI: 3
  • HAC: 26
  • HDO: 13
  • TPSA: 426.80
  • ALOGS: -5.41
  • ROTB: 33

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 21, 1976 FDA BRACCO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple use of single-use product 215.39 89.73 21 58 47 2357959
Therapeutic product effect decreased 175.54 89.73 31 48 10758 2347248

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC V04CC03 VARIOUS
DIAGNOSTIC AGENTS
OTHER DIAGNOSTIC AGENTS
Tests for bile duct patency
FDA Chemical/Ingredient N0000007750 Cholecystokinin
FDA EPC N0000175798 Cholecystokinin Analog

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diagnostic aid indication 2949005
Diagnostic Test for Pancreas Function indication
Gastrointestinal obstruction contraindication 126765001
Pregnancy, function contraindication 289908002
Gallstone Complications contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.68 acidic
pKa2 3.79 acidic
pKa3 12.75 acidic
pKa4 12.79 acidic
pKa5 13.18 acidic
pKa6 13.27 acidic
pKa7 13.67 acidic
pKa8 13.79 acidic
pKa9 8.42 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cholecystokinin receptor type A GPCR Ki 9.55 CHEMBL
Gastrin/cholecystokinin type B receptor GPCR Ki 9.55 CHEMBL
Cholecystokinin receptor type A GPCR Ki 9.55 CHEMBL
Gastrin/cholecystokinin type B receptor GPCR Ki 9.39 CHEMBL
Cholecystokinin receptor GPCR Ki 9.52 CHEMBL
Cholecystokinin receptor type A GPCR Ki 10.05 CHEMBL
Gastrin/cholecystokinin type B receptor GPCR IC50 9.52 CHEMBL

External reference:

IDSource
D05845 KEGG_DRUG
4017721 VUID
N0000146090 NUI
C0037167 UMLSCUI
126222003 SNOMEDCT_US
4017721 VANDF
9800 RXNORM
35765001 SNOMEDCT_US
5466 MMSL
d03895 MMSL
001215 NDDF
CHEMBL1121 ChEMBL_ID
M03GIQ7Z6P UNII
3617 INN_ID
DB09142 DRUGBANK_ID
CHEBI:135946 CHEBI
D012844 MESH_DESCRIPTOR_UI
9833444 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
KINEVAC HUMAN PRESCRIPTION DRUG LABEL 1 0270-0556 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 ug INTRAVENOUS NDA 16 sections
SIncalide HUMAN PRESCRIPTION DRUG LABEL 1 51808-203 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 ug INTRAVENOUS Unapproved drug other 8 sections